U.S. Renewable Energy Stock News

In recent weeks, Ionis Pharmaceuticals has highlighted new Phase 3 data for olezarsen in severe hypertriglyceridemia and partner GSK reported positive pivotal results for the antisense hepatitis B therapy bepirovirsen, while the company also prepared additional olezarsen analyses for presentation at upcoming medical meetings. These updates collectively emphasize Ionis’s advancing late-stage antisense pipeline across cardiovascular, metabolic, and liver diseases, reinforcing how partnered and...

How Boyd Gaming stock has been performing Boyd Gaming (BYD) has moved in different directions over recent periods, with the stock down 0.6% over the past day but higher over the past week, month and past 3 months. Over the past week the stock is up 6.3%, while the month shows a 2.6% gain and the past 3 months show a 9.2% rise. Year to date, Boyd Gaming is up 1.9%, and over the past year the total return stands at 19.7%. Looking further back, the stock shows a 32.4% total return over 3 years...

In late May 2026, American Healthcare REIT reported Q1 normalized FFO of US$0.50, delivered its ninth consecutive quarter of double-digit same-store NOI growth, raised full-year 2026 guidance, and completed a discounted public equity offering of 14,000,000 shares to strengthen its balance sheet. Analysts highlighted the company’s RIDEA and senior housing operations, together with improved financial flexibility after the equity raise, as reinforcing its ability to pursue growth initiatives...

Arrowhead Pharmaceuticals recently presented interim Phase 1/2a data for obesity and MASH candidate ARO-INHBE and new clinical findings for triglyceride-lowering therapy plozasiran, while also outlining upcoming clinical and commercial milestones during its Jefferies Global Healthcare Conference 2026 appearance. The emerging profile of ARO-INHBE as a potential infrequently dosed obesity and MASH treatment, together with expanded plozasiran data in patients with renal and hepatic impairment,...

In recent days, Expand Energy Corporation disclosed a shift toward gas marketing and commercial optimization to strengthen margins and free cash flow, while Barclays lowered its analyst rating on the company amid a reduced gas outlook and fewer visible short-term catalysts. At the same time, Expand Energy has been deepening its commercial footprint through a new offtake agreement with Delfin LNG and additional term sales and firm transportation commitments, signaling a stronger emphasis on...

Former President Donald Trump disclosed buying up to US$5.1 million of Dell Technologies (NYSE:DELL) stock shortly before publicly praising the company. The timing of the trades and later endorsements has sparked conflict of interest debates and broad national media coverage. Senator Elizabeth Warren has called for a congressional investigation, arguing the trades highlight potential corruption and misuse of public influence. Dell Technologies, traded as NYSE:DELL, is a major provider of...

UroGen Pharma (URGN) has come into focus after announcing a settlement and license agreement with Teva Pharmaceuticals covering Jelmyto. The deal clarifies future generic entry timing and removes ongoing patent litigation risk around this cancer treatment. See our latest analysis for UroGen Pharma. Recent news around Jelmyto has come as the stock cools slightly in the very short term, with the 30 day share price return down 8.67% and the 7 day share price return down 4.55%. This has occurred...

In early June 2026, Celcuity Inc. priced an upsized underwritten offering of US$500,000,000 in 0.250% convertible senior notes due 2032, planning to repay its Oxford Finance loan and fund clinical, commercialization and general corporate needs, including potential acquisitions. The detailed Phase 3 VIKTORIA-1 results for gedatolisib in PIK3CA-mutant advanced breast cancer, including efficacy, safety and a planned supplemental FDA filing, now sit alongside this new convertible debt as...

Marriott International (MAR) is back in focus after expanding its partnership with ResortPass to broaden day-access spa and wellness offerings, tying local guest demand and amenity usage more closely to the stock’s current investment story. See our latest analysis for Marriott International. Investors have been rewarding this focus on monetizing amenities, with a 30 day share price return of 11.14% and year to date share price return of 25.24% sitting alongside a 1 year total shareholder...

Jazz Pharmaceuticals (JAZZ) has moved back into focus after a cluster of updates on its sleep and oncology portfolios, including 21 planned Xywav data presentations at SLEEP 2026 and recently published Phase 3 Ziihera results. See our latest analysis for Jazz Pharmaceuticals. Recent updates around Xywav and Ziihera, together with quarterly results that exceeded expectations, have arrived against a backdrop of strong momentum. A 90 day share price return of 28.68% and a 1 year total...

Recent move in Impinj (PI) stock Impinj (PI) has drawn investor attention after a recent pullback, with the stock down 11.2% over the past day and 20.9% over the past month, despite a 22.4% gain over the past 3 months. That mix of shorter term weakness and recent quarter strength is prompting closer scrutiny of the company’s US$3.7b valuation, its RAIN RFID focused business model, and the current gap between share price and fundamental performance. See our latest analysis for Impinj. With the...

We wouldn't blame NovoCure Limited ( NASDAQ:NVCR ) shareholders if they were a little worried about the fact that Frank...

Recent debate around Tapestry (TPR) has intensified as differing valuation views, insider share sales and a softer backdrop for luxury stocks converge. This has prompted investors to reassess the company’s growth outlook and profit profile. See our latest analysis for Tapestry. Tapestry’s share price has pulled back over the past week, with a 7 day share price return of 3.68% and a 90 day share price return of 3.71% decline. However, the 1 year total shareholder return of 79.74% and 5 year...

CEO commentary puts Karooooo (KARO) in focus Fresh comments from Karooooo (KARO) CEO Zak Calisto on accelerating subscription revenue growth, strong free cash flow and international expansion have put the stock back on many investors’ watchlists. Together with upbeat analyst views on earnings estimate revisions and reported fundamentals, this recent commentary is shaping how investors assess Karooooo’s growth profile and risk balance today. See our latest analysis for Karooooo. Karooooo’s...

In early June 2026, CRISPR Therapeutics AG filed a shelf registration for up to US$969.16 million in common shares linked to its employee stock plans, shortly after shareholders approved amendments to the company’s articles of association at the annual meeting. Coming on the heels of high-profile conference presentations and growing attention to its Casgevy launch and cardiovascular gene-editing pipeline, these corporate moves highlight how CRISPR Therapeutics is building financial and...

Lamb Weston Holdings (LW) plans to close its Broekhuizenvorst, Netherlands production facility, affecting about 110 employees, as part of its Focus to Win supply chain realignment in response to current market conditions. See our latest analysis for Lamb Weston Holdings. The Broekhuizenvorst closure headlines come after a weak run for the stock, with the latest share price at US$42.12 and the 1 year total shareholder return down 22.08%, while 3 and 5 year total shareholder returns also show...

In late May and early June 2026, Abbott highlighted new data showing rising, often-missed diabetic ketoacidosis cases and secured CE Mark approval in Europe for Libre Duo and Libre Duo 10 Day, its first-of-its-kind dual glucose‑ketone continuous monitoring systems, while awaiting U.S. FDA clearance. The combination of alarming national trends in DKA-related hospitalizations and Abbott’s dual-analyte sensor positions the company to address a critical gap in diabetes care. We’ll now examine...

Driven Brands Holdings Inc. previously received a Nasdaq notice after delaying its First Quarter 2026 10-Q filing, following an earlier restatement-driven delay to its 2025 10-K, and now has until July 31, 2026 to submit a compliance plan and up to November 25, 2026 to regain full listing compliance. While the notice has no immediate effect on the Nasdaq listing, the filing delay and prior restatement focus attention on Driven Brands’ financial reporting controls and timeline for returning...

Pharvaris (PHVS) is back in focus after announcing that eight deucrictibant abstracts, including Phase 3 and long term safety data, have been accepted for presentation at the 2026 European Academy of Allergy and Clinical Immunology Congress. See our latest analysis for Pharvaris. At a share price of US$31.09, Pharvaris has seen a 17.4% year to date share price return and an 85.3% total shareholder return over one year. The 1 day move was a modest pullback that contrasts with stronger 90 day...

Capricor Therapeutics recently cleared a key hurdle for its lead Duchenne muscular dystrophy therapy Deramiocel, completing an FDA Pre-License Inspection at its San Diego GMP facility and securing a Prescription Drug User Fee Act (PDUFA) decision date in August for its Biologics License Application. This combination of regulatory progress, manufacturing readiness, and cash runway reportedly extending through the fourth quarter of 2027 gives Capricor unusual visibility on its ability to fund...

In its first full quarter since combining with MRC Global, DNOW reported strong revenue growth but weaker profitability, citing ERP transition costs, lower U.S. volumes, and integration efforts that included raising expected 2026 cost synergies to about US$30 million and acquiring Edge Controls to broaden its automation capabilities. At the same time, Rosen Law Firm began investigating potential securities claims over allegedly misleading past disclosures, adding a legal overhang just as...

Ventas stock performance snapshot Ventas (VTR) has drawn investor attention after a mixed recent performance, with the stock up 3.7% in the past day but down over the past week, month and past 3 months. Over the past year, Ventas has delivered a 32.4% total return and is up 6.1% year to date. This gives investors a reference point against its longer term 3 year and 5 year total returns. See our latest analysis for Ventas. The recent 1 day share price return of 3.7% to US$82.02 comes after...

GPGI (GPGI) is back in focus after shareholders approved a move to shift the company’s corporate domicile from Delaware to Nevada. This governance change will be formally detailed in an upcoming Form 8-K filing. See our latest analysis for GPGI. The governance shift to Nevada comes at a time when the stock has been under pressure, with the 30 day share price return down 14.34% and the 90 day share price return down 42.42%, even though the 3 year total shareholder return sits at 112.30%. This...

Geopolitical shocks in the Gulf, higher oil prices, and disrupted trade routes are reshaping the risk and opportunity profile for energy related stocks. For investors, this kind of tension can quickly change which companies are better placed to handle supply risks, cost pressures, and swings in demand. This article focuses on three large oil and gas producers from a curated screener that targets size and financial strength. Each stock is exposed to the current news backdrop in different ways,...